Inflammatory response to urate crystals

The inflammatory response to urate crystals is a biological process central to the pathogenesis of gout, a disease characterized by painful joint inflammation resulting from the deposition of monosodium urate (MSU) crystals[1][4][5][6]. MSU crystals, formed by the precipitation of uric acid in supersaturated environments, activate several innate immune pathways. Key steps include activation of resident macrophages and neutrophils, release of pro-inflammatory cytokines (especially IL-1β via NLRP3 inflammasome activation), complement system activation, and formation of neutrophil extracellular traps (NETs)[4][6][3][2]. While the crystals themselves are not druggable targets, several proteins and pathways involved in the process—such as NLRP3, IL-1β, and complement components—are considered therapeutic targets for treating gout and related inflammatory conditions. Drugs most commonly used act upstream (by lowering urate levels[1][6]), downstream (cytokine antagonists), or block key steps in the inflammatory cascade. This entry is not a correct molecular target—it is a process description. For isolated molecular targets involved in this response, see "NLRP3 inflammasome," "Interleukin-1β," "Clec12A," "SIRL-1," or complement components.

Other names

Inflammatory response to monosodium urate crystalsGout-associated inflammatory responseCrystal-induced inflammation

relevant mechanisms include inhibition of inflammasome activation, cytokine blockade, neutrophil recruitment inhibition